All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Frontline Aumolertinib Plus Anlotinib Elicits Responses in EGFR-Mutant NSCLC With Brain Metastases

November 26th 2023

Aumolertinib plus anlotinib resulted in intracranial efficacy when used in the first-line treatment of patients with EGFR-mutant non–small cell lung cancer who have brain metastases.

The US Oncology Network Extends Its Reach into Tennessee with The Addition of Nashville Oncology Associates

November 25th 2023

The Network continues its strong growth trajectory and its mission to enhance community-based cancer care.

AON Joins Nasdaq to Further Patient-Centric Community Oncology Care

November 25th 2023

The American Oncology Network has started trading on Nasdaq with the goal of continuing the growth of the organization.

Fox Chase Cancer Center’s Dr. Elizabeth Plimack Named a Fellow of the American Society of Clinical Oncology

November 24th 2023

Elizabeth Plimack, MD, MS, Deputy Director and Professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, was recently recognized as a new fellow of the American Society of Clinical Oncology.

Rutgers Research Summit Aims to Broaden Oncologic Perspectives Across New Jersey

November 24th 2023

Andrew Evens, DO, MBA, MSc, highlights key points presented during the 2023 Rutgers Cancer Institute of New Jersey’s Annual Oncology Clinical Practice and Research Summit, the clinical implications of these presentations, and lymphoma treatment innovations that Rutgers Cancer Institute is providing to patients throughout New Jersey.

BASECAMP-1 Trial Aims to Identify Patients With Solid Tumors Who Are Eligible for A2B530

November 24th 2023

The observational BASECAMP-1 screening study has started to identify patients with advanced solid tumors harboring somatic human leukocyte antigen-A*02 loss of heterozygosity who would be eligible to receive the novel Tmod CAR T-cell therapy, A2B530, if their cancer relapses after standard of care treatment.

Promising New Treatment Minimizes Negative Side Effects of Chemotherapy for Small Cell Lung Cancer Patients

November 23rd 2023

Research conducted by Florida Cancer Specialists & Research Institute, LLC recently confirmed the effectiveness of a new medication in protecting bone marrow of patients who receive chemotherapy for extensive-stage small cell lung cancer.

Novel Immunomodulatory Vaccine Plus Pembrolizumab Shows Early Activity in PD-L1–High NSCLC Adenocarcinoma

November 23rd 2023

Jonathan W. Riess, MD, MS, discusses how prior data led to the investigation of IO102-IO103 in combination with pembrolizumab in patients with PD-L1–high non–small cell lung cancer adenocarcinoma and details the initial efficacy and safety data reported in this population.

Selinexor Maintenance Leads to PFS Benefit in TP53 Wild-Type Advanced/Recurrent Endometrial Cancer

November 22nd 2023

Maintenance therapy with selinexor improved progression-free survival compared with placebo in patients with TP53 wild-type advanced or recurrent endometrial cancer, regardless of microsatellite instability status.

Fruquintinib Approval Highlights Strides Made in mCRC Armamentarium in 2023

November 22nd 2023

Cathy Eng, MD, FACP, FASCO, discusses the implications of the fruquintinib approval, as well as other key clinical trial data and regulatory decisions within the colorectal cancer realm in 2023; the importance of early molecular testing in this patient population; and the continued importance of enrolling eligible patients onto clinical trials.

Toripalimab Approval Pioneers Immunotherapy Use in Nasopharyngeal Cancer

November 22nd 2023

Nabil F. Saba, MD, FACP, and Shravan Kandula, MD, highlight the significance of the approval of toripalimab for nasopharyngeal carcinoma; key data from JUPITER-02 and POLARIS-02 trials; and how the addition of this agent to the treatment armamentarium heightens the importance of multidisciplinary collaboration.

Dato-DXd Plus Durvalumab Elicits Durable Responses in Metastatic TNBC Regardless of PD-L1 Status

November 22nd 2023

Peter Schmid, FRCP, MD, PhD, discusses the evaluation of combination of the datopotamab deruxtecan and durvalumab in patients with first-line triple-negative breast cancer, details safety and efficacy findings derived from the combination in the BEGONIA trial, and highlights ongoing efforts with this combination.

Taletrectinib Under NMPA Review in China for Advanced or Metastatic ROS1+ NSCLC

November 22nd 2023

The Center for Drug Evaluation of China’s National Medical Products Administration has accepted the new drug application seeking the approval of the next-generation ROS1 TKI taletrectinib for the treatment of patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer with prior exposure to a ROS1 TKI.

Bayer Recalls Oral Larotrectinib Solution Because of Microbial Contamination

November 22nd 2023

Bayer has voluntarily recalled 1 lot of the larotrectinib 20 mg/mL oral solution that is packaged in 100-mL glass bottles because of the presence of Penicillium brevicompactum contamination that was observed during ongoing, routine stability testing.

Sugemalimab Receives Approval in China for Relapsed/Refractory Extranodal NK/T-cell Lymphoma

November 22nd 2023

The National Medical Products Administration of China has approved sugemalimab for use in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma.

SCO-101 Plus FOLFIRI Prolongs Survival in Metastatic Colorectal Cancer

November 22nd 2023

SCO-101 in combination with leucovorin, fluorouracil, and irinotecan (FOLFIRI) prolonged survival in heavily pretreated patients with metastatic colorectal cancer who had no other active treatment options available, according to final data from part 2 of the phase 2 CORIST study.

Fixed-Duration Approaches Provide Promising Survival Benefit for Select Patients With CLL

November 21st 2023

John N. Allan, MD, discusses current data detailing the activity of venetoclax-based, fixed-duration regimens in the frontline setting for patients with chronic lymphocytic leukemia; the synergy and promising efficacy signals seen with BCL-2 and BTK inhibitor combinations; and ongoing research efforts exploring triplet regimens vs other continuous approaches in this space.

Overcoming Resistance Mutations Is a Focus for Novel Therapies in R/R CLL

November 21st 2023

Nicole Lamanna, MD, discusses the challenges of resistance in patients with CLL, highlights treatment being developed for patients who progress on BTK inhibitor– or venetoclax-based regimens, and emphasizes the need for further enrollment onto clinical trials.

Emerging Therapeutic Targets Are Expanding the CLL Treatment Armamentarium

November 21st 2023

Bhagirathbhai Dholaria, MBBS, discusses limitations in the current CLL standards of care that necessitate more effective therapies; BTK inhibitors and degraders on the horizon for this population; and the potential future role of CAR T-cell therapy for patients with CLL.

Ongoing Research Aims to Bring Bispecific Antibodies to Earlier Settings and Novel Combinations in Myeloma

November 21st 2023

Joshua Richter, MD, provides an overview of the current state of bispecific antibodies in multiple myeloma, discusses ongoing investigations of these agents, and expands on their unique toxicities and the need for proactive management.